Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
NCT06664151

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Led by Dana-Farber Cancer Institute · Updated on 2025-10-02

25

Participants Needed

2

Research Sites

91 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot)

CONDITIONS

Official Title

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of cutaneous squamous cell carcinoma confirmed by biopsy, including mixed histology types
  • Skin tumor size between 10 and 39 mm in longest dimension by clinical exam
  • Candidate for treatment by Mohs micrographic surgery
  • Age 18 years or older
  • ECOG performance status 0 to 3 (Karnofsky 40% or higher)
  • Ability and willingness to sign informed consent
  • For HIV patients, on effective anti-retroviral therapy with undetectable viral load within 6 months
  • For hepatitis B patients, undetectable viral load on suppressive therapy if needed
  • For hepatitis C patients, treated and cured or currently on treatment with undetectable viral load
Not Eligible

You will not qualify if you...

  • High-risk CSCC features such as peri-neural invasion >0.1 mm, invasion beyond subcutaneous fat, or tumor diameter over 3.9 cm
  • Evidence of metastases including in-transit/satellite, nodal, or distant from CSCC
  • History of solid organ or allogeneic bone marrow transplant
  • History of allergic reactions to seasonal flu vaccine
  • History of Guillain-Barré syndrome
  • Uncontrolled illnesses including severe cardiac disease or recent myocardial infarction
  • Receiving other investigational cancer treatments
  • Past malignancies likely to interfere with study safety or efficacy assessments
  • Psychiatric or social conditions limiting study compliance
  • Women of child-bearing potential and men must agree to use contraception during and after the study
  • Pregnant or nursing women
  • Routine flu vaccination history does not exclude participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02215

Actively Recruiting

2

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

Loading map...

Research Team

K

Karam Khaddour, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here